Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

被引:1020
作者
Olive, KP
Tuveson, DA
Ruhe, ZC
Yin, B
Willis, NA
Bronson, RT
Crowley, D
Jacks, T
机构
[1] MIT, Ctr Canc Res, Cambridge, MA 02139 USA
[2] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
[3] Tufts Univ, Sch Vet, Dept Biomed Sci, North Grafton, MA 01536 USA
[4] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA
关键词
D O I
10.1016/j.cell.2004.11.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The p53 tumor suppressor gene is commonly altered in human tumors, predominantly through missense mutations that result in accumulation of mutant p53 protein. These mutations may confer dominant-negative or gain-of-function properties to p53. To ascertain the physiological effects of p53 point mutation, the structural mutant p53(R172H) and the contact mutant p53(R270H) (codons 175 and 273 in humans) were engineered into the endogenous p53 locus in mice. p53(R270H/+) and p53(R172H/-) mice are models of Li-Fraumeni Syndrome; they developed allele-specific tumor spectra distinct from p53(+/-) mice. In addition, p53(R270H/-) and p53(R172H/-) mice developed novel tumors compared to p53(-/-) mice, including a variety of carcinomas and more frequent endothelial tumors. Dominant effects that varied by allele and function were observed in primary cells derived from p53(R270H/+) and p53(R172H/+), mice. These results demonstrate that point mutant p53 alleles expressed under physiological control have enhanced oncogenic potential beyond the simple loss of p53 function.
引用
收藏
页码:847 / 860
页数:14
相关论文
共 56 条
[1]   p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines [J].
Aurelio, ON ;
Kong, XT ;
Gupta, S ;
Stanbridge, EJ .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (03) :770-778
[2]  
BAKER SJ, 1990, CANCER RES, V50, P7717
[3]   Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome [J].
Birch, JM ;
Blair, V ;
Kelsey, AM ;
Evans, DG ;
Harris, M ;
Tricker, KJ ;
Varley, JM .
ONCOGENE, 1998, 17 (09) :1061-1068
[4]   The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth [J].
Cadwell, C ;
Zambetti, GP .
GENE, 2001, 277 (1-2) :15-30
[5]   Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients [J].
Casciano, I ;
Mazzocco, K ;
Boni, L ;
Pagnan, G ;
Banelli, B ;
Allemanni, G ;
Ponzoni, M ;
Tonini, GP ;
Romani, M .
CELL DEATH AND DIFFERENTIATION, 2002, 9 (03) :246-251
[6]   CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS [J].
CHO, YJ ;
GORINA, S ;
JEFFREY, PD ;
PAVLETICH, NP .
SCIENCE, 1994, 265 (5170) :346-355
[7]  
CORDONCARDO C, 1994, CANCER RES, V54, P794
[8]   Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function [J].
de Vries, A ;
Flores, ER ;
Miranda, B ;
Hsieh, HM ;
van Oostrom, CTM ;
Sage, J ;
Jacks, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) :2948-2953
[9]   DETECTION OF A TRANSFORMATION-RELATED ANTIGEN IN CHEMICALLY-INDUCED SARCOMAS AND OTHER TRANSFORMED-CELLS OF THE MOUSE [J].
DELEO, AB ;
JAY, G ;
APPELLA, E ;
DUBOIS, GC ;
LAW, LW ;
OLD, LJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (05) :2420-2424
[10]  
Di Como CJ, 1999, MOL CELL BIOL, V19, P1438